234 related articles for article (PubMed ID: 30867811)
21. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
[TBL] [Abstract][Full Text] [Related]
22. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.
Boboila S; Lopez G; Yu J; Banerjee D; Kadenhe-Chiweshe A; Connolly EP; Kandel JJ; Rajbhandari P; Silva JM; Califano A; Yamashiro DJ
Oncogene; 2018 Oct; 37(40):5451-5465. PubMed ID: 29880876
[TBL] [Abstract][Full Text] [Related]
23. Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN.
Zhang X; Cong X; Jin X; Liu Y; Zhang T; Fan X; Shi X; Zhang X; Wang X; Yang YG; Dai X
Cell Death Dis; 2023 Aug; 14(8):504. PubMed ID: 37543638
[TBL] [Abstract][Full Text] [Related]
24. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
25. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
[TBL] [Abstract][Full Text] [Related]
26. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
27. A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells.
Zhao Z; Ma X; Shelton SD; Sung DC; Li M; Hernandez D; Zhang M; Losiewicz MD; Chen Y; Pertsemlidis A; Yu X; Liu Y; Du L
Oncotarget; 2016 Nov; 7(48):79372-79387. PubMed ID: 27764804
[TBL] [Abstract][Full Text] [Related]
28. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
29. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
[TBL] [Abstract][Full Text] [Related]
30. MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.
Beckers A; Van Peer G; Carter DR; Gartlgruber M; Herrmann C; Agarwal S; Helsmoortel HH; Althoff K; Molenaar JJ; Cheung BB; Schulte JH; Benoit Y; Shohet JM; Westermann F; Marshall GM; Vandesompele J; De Preter K; Speleman F
Cancer Lett; 2015 Sep; 366(1):123-32. PubMed ID: 26123663
[TBL] [Abstract][Full Text] [Related]
31. Lineage specific transcription factor waves reprogram neuroblastoma from self-renewal to differentiation.
Banerjee D; Bagchi S; Liu Z; Chou HC; Xu M; Sun M; Aloisi S; Vaksman Z; Diskin SJ; Zimmerman M; Khan J; Gryder B; Thiele CJ
Nat Commun; 2024 Apr; 15(1):3432. PubMed ID: 38653778
[TBL] [Abstract][Full Text] [Related]
32. LncRNA SNHG1 regulates neuroblastoma cell fate via interactions with HDAC1/2.
Hsu CL; Yin CF; Chang YW; Fan YC; Lin SH; Wu YC; Huang HC; Juan HF
Cell Death Dis; 2022 Sep; 13(9):809. PubMed ID: 36130928
[TBL] [Abstract][Full Text] [Related]
33. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
34. Essential role of GATA3 in regulation of differentiation and cell proliferation in SK-N-SH neuroblastoma cells.
Peng H; Ke XX; Hu R; Yang L; Cui H; Wei Y
Mol Med Rep; 2015 Feb; 11(2):881-6. PubMed ID: 25351211
[TBL] [Abstract][Full Text] [Related]
35. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Utility of GATA3 and ISL1 in Differentiating Neuroblastoma From Other Pediatric Malignant Small Round Blue Cell Tumors.
Mohanty SK; Diwaker P; Mishra SK; Jha S; Lobo A; Panda SP; Sharma S; Kumar M; Arora S; Mallik V; Jain D; Jain E; Chakrabarti I; Varshney J; Beg A; Dixit M; Baisakh MR; Naik S; Sahoo SK; Akgul M; Balzer BL; Amin MB; Parwani AV
Int J Surg Pathol; 2024 Apr; 32(2):294-303. PubMed ID: 37312579
[TBL] [Abstract][Full Text] [Related]
37. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
[TBL] [Abstract][Full Text] [Related]
38. SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.
Hu X; Liu R; Hou J; Peng W; Wan S; Xu M; Li Y; Zhang G; Zhai X; Liang P; Cui H
Oncogene; 2022 Sep; 41(37):4295-4306. PubMed ID: 35978151
[TBL] [Abstract][Full Text] [Related]
39. L1-CAM knock-down radiosensitizes neuroblastoma IMR-32 cells by simultaneously decreasing MycN, but increasing PTEN protein expression.
Rached J; Nasr Z; Abdallah J; Abou-Antoun T
Int J Oncol; 2016 Oct; 49(4):1722-30. PubMed ID: 27432152
[TBL] [Abstract][Full Text] [Related]
40. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Amente S; Milazzo G; Sorrentino MC; Ambrosio S; Di Palo G; Lania L; Perini G; Majello B
Oncotarget; 2015 Jun; 6(16):14572-83. PubMed ID: 26062444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]